Teva settles with Pfizer on arthritis treatment

Brand Celebrex has $2.2 billion in US sales in 2013, according to IMS data.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has settled with Pfizer Inc. (NYSE: PFE; LSE: PFZ) on Teva’s generic version of Pfizer's arthritis drug Celebrex capsules in the US. Under the terms of the settlement, Teva may launch its generic versions in December 2014, or earlier under certain circumstances.

Brand Celebrex has $2.2 billion in US sales in 2013, according to IMS data.

Teva has received Tentative Approval from the US Food and Drug Administration (FDA) for all strengths of generic Celebrex, and believes that it is first-to-file on at least the 100, 200 and 400 mg capsules.

Published by Globes [online], Israel business news - www.globes-online.com - on April 17, 2014

© Copyright of Globes Publisher Itonut (1983) Ltd. 2014

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018